<DOC>
	<DOCNO>NCT00001402</DOCNO>
	<brief_summary>The human heart divide four chamber . One four chamber , leave ventricle , chamber mainly responsible pump blood heart circulation . Diseases heart like congestive heart failure ( CHF ) , cause leave ventricle function improperly . Medications call beta-blockers appear reverse abnormality leave ventricle frequently improve function leave ventricle patient different kind heart disease . How beta-blockers improve leave ventricle function unknown . One possible reason improve function leave ventricle beta-blockers improve blood flow heart muscle . When region heart active , use fuel form oxygen sugar ( glucose ) . As heart activity increase , blood flow area activity increase also . Knowing fact , researcher use radioactive sugar ( glucose ) positron emission tomography ( PET ) scan observe area heart receive blood flow . In study researcher plan measure glucose use heart muscle blood flow heart muscle patient CHF take beta-blockers .</brief_summary>
	<brief_title>PET Scan Determine Areas Blood Flow Activity Hearts Patients With Heart Disease Taking Beta-Blockers</brief_title>
	<detailed_description>Deterioration leave ventricular function , characteristic patient congestive heart failure , appear multifactorial process . Beta-blockers appear reverse deterioration frequently improve leave ventricular function patient ischemic non-ischemic cardiomyopathy . The mechanism beta-blockers improve ejection fraction know . Although well establish regional flow , function metabolism may improve coronary revascularization whether beta-blocker therapy similar salutary result patient congestive heart failure unknown . The aim study : 1 ) quantitate regional glucose uptake regional blood flow chronic beta-blocker administration patient congestive heart failure use positron emission tomography , 2 ) determine alteration either regional glucose lipid uptake regional blood flow correlate improvement wall motion global leave ventricular function , 3 ) determine ischemic nonischemic myocardium differ blood flow metabolism .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>Left ventricular ejection fraction radionuclide angiography less equal 40 % . New York Heart Association class II , III IV symptom standard heart failure medication include digoxin , diuretic angiotensin convert enzyme inhibitor least one month prior enrollment . Ischemic cardiomyopathy enzyme document MI 70 % great stenosis one major vessel . Dilated cardiomyopathyif coronary disease . No pregnant lactate woman . No woman childbearing age proven birth control . No severe hepatic renal disease . No diabetes mellitus fast glucose great equal 120 mg/dl . No primary valvular heart disease . No PTCA CABG within 3 month enrollment . No history myocardial infarction unstable angina within past 2 month . No rest heart rate le 60 bpm . No AV block great 1 degree block without pacemaker . No severe ETOH abuse within 6 month enrollment . No severe bronchospasm .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1999</verification_date>
	<keyword>Dilated Cardiomyopathy</keyword>
	<keyword>Hibernating Myocardium</keyword>
	<keyword>Ischemic Cardiomyopathy</keyword>
	<keyword>Metoprolol</keyword>
	<keyword>Stress Thallium Scintigraphy</keyword>
	<keyword>Congestive Cardiomyopathy</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Heart Failure</keyword>
</DOC>